1 March 2016
Merck Animal Health Highlights Commitment to Sustainable Salmon Farming at 2016 North Atlantic Seafood Forum
MADISON, N.J., March 1, 2016 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced its renewed commitment to sustaining salmon farming through participation in the 2016 North Atlantic Seafood Forum (NASF), being held in Bergen, Norway from March 1-3, 2016.
Disease and poor health are among the top major constraints for sustainable aquaculture. Merck Animal Health is committed to developing responsible products to maximize fish survival, growth and production efficiency for salmon and other farmed fish species. The key to sustainable aquaculture is maintenance of health control and the availability of safe and effective products for the prevention and control of diseases. Merck Animal Health has been at the forefront of developing those products with the industry.
“Salmon farming has grown enormously over the past decades to meet the demand for fish protein, and Merck Animal Health has been at the forefront of sustainable farming and disease prevention and control,” said Rick DeLuca, president, Merck Animal Health. “We are pleased to participate in the largest seafood conference to share ideas, science and partner with experts and our customers.”
“Merck Animal Health has more than 30 years of history of developing vaccines for the salmon industry and our vaccines have been an important contributor to the Norwegian sustainable and renewable aquaculture industry,” said Johan Kvalheim, Managing Director, Norway, Merck Animal Health. “This commitment extends to our R&D location in Bergen, Merck Animal Health Innovation, which is dedicated to the development of vaccines for cold water species of fish in Norway, and globally.”
For more information about the North Atlantic Seafood Forum, visit http://www.nor-seafood.com/.
About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).